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The mutational status of the immunoglobulin heavy chain
variable region defines two clinically distinct forms of
chronic lymphocytic leukemia (CLL) known as mutated
(M-CLL) and unmutated (UM-CLL). To elucidate the mo-
lecular mechanisms underlying the adverse clinical out-
come associated with UM-CLL, total proteomes from nine
UM-CLL and nine M-CLL samples were analyzed by iso-
baric tags for relative and absolute quantification (iTRAQ)-
based mass spectrometry. Based on the expression of
3521 identified proteins, principal component analysis
separated CLL samples into two groups corresponding to
immunoglobulin heavy chain variable region mutational
status. Computational analysis showed that 43 cell migra-
tion/adhesion pathways were significantly enriched by 39
differentially expressed proteins, 35 of which were ex-
pressed at significantly lower levels in UM-CLL samples.
Furthermore, UM-CLL cells underexpressed proteins as-
sociated with cytoskeletal remodeling and overexpressed
proteins associated with transcriptional and translational
activity. Taken together, our findings indicate that UM-
CLL cells are less migratory and more adhesive than M-
CLL cells, resulting in their retention in lymph nodes,
where they are exposed to proliferative stimuli. In keeping
with this hypothesis, analysis of an extended cohort of 120
CLL patients revealed a strong and specific association
between UM-CLL and lymphadenopathy. Our study illus-
trates the potential of total proteome analysis to elucidate
pathogenetic mechanisms in cancer. Molecular & Cel-
lular Proteomics 14: 10.1074/mcp.M114.044479, 933–945,
2015.
Chronic lymphocytic leukemia (CLL)1 is the most common
adult leukemia in Western countries. It is characterized by the
clonal expansion of antigen-experienced B cells with a dis-
tinctive immunophenotype (1, 2). The disease runs a highly
variable clinical course, with some patients surviving for de-
cades without treatment and others dying from drug-resistant
disease within a year of presentation (3).
Many biological variables have been identified in CLL that
correlate with clinical outcome. Among these variables, the
somatic mutational status of the immunoglobulin heavy chain
variable region (IGHV) gene expressed by the malignant clone
has a unique biological importance as it is the only prognostic
biomarker that is fixed at the initiation of clonal expansion,
inherited by the entire malignant clone, and stable over time
(4–6). Furthermore, because somatic hypermutation is tightly
regulated during B cell development, IGHV mutational status
provides insight into the clonogenic cell of origin in CLL.
Specifically, cases of CLL with mutated IGHV genes (M-CLL)
are thought to arise from a memory B cell that has encoun-
tered a T cell-dependent antigen, whereas those with unmu-
tated IGHV genes (UM-CLL) are thought to arise from a B cell
that has reacted to a T-independent antigen (7). Importantly,
From the ‡Department of Molecular and Clinical Cancer Medicine,
§MRC Centre for Drug Safety Science, Department of Molecular and
Clinical Pharmacology, University of Liverpool, Liverpool L69 3GA,
UK; ¶Royal Liverpool and Broadgreen University Hospitals NHS
Trust, Liverpool L7 8XP, UK
Author’s Choice—Final version full access.
Received January 30, 2015 and in revised form, January 30, 2015
Published, MCP Papers in Press, February 2, 2015, DOI 10.1074/
mcp.M114.044479
Author contributions: J.Z., N.R.K., and A.R.P. designed research;
G.L.E. performed research; G.L.E., J.Z., P.V.J., N.R.K., and A.R.P.
analyzed data; G.L.E., J.Z., R.E.J., K.J.T., P.V.J., N.R.K., and A.R.P.
wrote the paper; R.E.J. generated MS data; K.J.T. generated migra-
tion assay data; K.L. and G.G.J. characterized clinical features of
patient samples; M.O. provided patient samples and clinical data;
K.P. contributed to the generation of MS data.
1 The abbreviations used are: CLL, chronic lymphocytic leukemia;
M-CLL, IGHV-mutated CLL; UM-CLL, IGHV-unmutated CLL; IGHV,
immunoglobulin heavy chain variable region; ACN, acetonitrile; MS,
mass spectrometry; iTRAQ, isobaric tags for relative and absolute
quantification; PANTHER, Protein Analysis Through Evolutionary Re-
lationships; MNDA, myeloid cell nuclear differentiation antigen; PCA,
principal component analysis.
Research
Author’s Choice © 2015 by The American Society for Biochemistry and Molecular Biology, Inc.
This paper is available on line at http://www.mcponline.org
Molecular & Cellular Proteomics 14.4 933
IGHV status is a strong and independent predictor of outcome
in CLL, with M-CLL being associated with a favorable out-
come and UM-CLL being associated with early disease pro-
gression and shorter survival (4–6).
Gene expression profiling studies have shown that, irre-
spective of their IGHV mutational status, CLL cells have an
mRNA signature similar to that of memory B cells (8, 9).
Although supervised clustering has shown that a number of
genes are differentially expressed in M-CLL and UM-CLL (8,
9), the molecular mechanisms responsible for the more ag-
gressive clinical course of UM-CLL remain incompletely un-
derstood. This may reflect the inability of mRNA profiling to
detect differences in protein expression due to post-tran-
scriptional regulation (10).
The advent of two-dimensional gel electrophoresis and
mass spectrometry (MS) in the mid-1990s represented a tech-
nological breakthrough in profiling gene expression at the
protein level (11, 12). Application of this technique to the
question of how M-CLL and UM-CLL differ from one another
has revealed a limited number of differentially expressed pro-
teins (the details of which are provided in supplemental Table
S1) (13–18). However, these studies have failed to provide a
convincing explanation for the adverse clinical outcome as-
sociated with UM-CLL.
The ability of two-dimensional gel electrophoresis and MS
to detect differences in protein expression is limited by the
fact that they provide only limited coverage of the proteome
and suffer from poor reproducibility (19). Recently, more pow-
erful gel-free techniques for proteomic analysis have been
developed, such as isobaric tags for relative and absolute
quantification (iTRAQ)-based MS. Here, we describe the ap-
plication of iTRAQ-based MS to analyze the total proteome of
nine M-CLL and nine UM-CLL samples. This approach has
enabled us to generate the largest quantity of proteomic
information for CLL to date and, in particular, to directly
compare the functions of differentially expressed proteins
between UM-CLL and M-CLL cells through a systems biology
approach. Our findings strongly support the idea that M-CLL
and UM-CLL are biologically distinct and suggest that the
adverse outcome associated with UM-CLL reflects the pro-
pensity of malignant cells to be retained in lymph nodes,
where they are induced to proliferate. In keeping with this
observation, we found a strong and specific association be-
tween UM-CLL and lymphadenopathy.
EXPERIMENTAL PROCEDURES
Sample Selection—All samples used for this study were obtained
with informed consent and with the approval of the North West 2
Research Ethics Committee–Liverpool Central. Samples were char-
acterized for IGHV mutational status as described below. Because
the extent of IGHV mutation in CLL varies continuously from 0 to
10%, a cutoff value of 2% was applied to distinguish M-CLL from
UM-CLL. This cutoff was used in the original studies describing the
prognostic importance of IGHV mutation (4, 5) and continues to be
applied (20). Nine cases were selected to represent extremely low
levels of IGHV mutation, and nine were selected to represent ex-
tremely high levels. Care was taken to ensure that other biological
variables of prognostic significance were evenly balanced between
the two groups. The clinical features of the 18 CLL samples used for
this study are shown in Table 1.
Preparation of CLL Samples—Venous blood was drawn from CLL
patients into tubes containing sodium heparin at a final concentration
of 10 units/1 ml of blood. Mononuclear cells were isolated by centri-
fugation of blood over Lymphoprep (Axis-Shield PoC AS, Oslo, Nor-
way) within 4 h of sampling and stored at 150 °C within 2 h of
separation. Analysis for recurrent chromosomal abnormalities was
performed as described previously (21). All mononuclear cell samples
used in the study contained 90% CD19 cells.
IGHV Mutational Analysis—Total RNA was extracted from CLL cells
using an RNeasy mini kit (Qiagen, Crawley, UK). 1 g of RNA was
reverse-transcribed with Moloney murine leukemia virus reverse tran-
scriptase (Promega, Southampton, UK) and an oligo(dT)15 primer.
Aliquots of the resulting cDNAs were used to identify clonally ex-
pressed IGHV in six PCRs, each with one of the six 5-leader primers
(22) and three mixed 3-primers specific for the immunoglobulin heavy
chain isotypes , , and  (23), respectively. The 50 microliter PCR
containing 20 pmol of each primer, 1.5 mM MgCl2, 100 M each
dNTP, and 2.5 units of Taq polymerase (Promega) was performed for
30 cycles by using a touch-down protocol, with the annealing tem-
perature reducing from 63 to 57 °C over the first 12 cycles. The PCR
products were visualized following electrophoresis. The amplified
clonal IGHV gene was purified using the Wizard SV Gel and PCR
Clean-up system (Promega), followed by Sanger sequencing from both
directions with the same primers used in PCR. The IGHV gene usage
and extent of somatic hypermutation were determined by comparison
to the nearest germ line counterpart sequence in the international Im-
MunoGeneTics information system with IMGT/V-QUEST.
Protein Extraction and iTRAQ Labeling—Protein was extracted
from CLL cells by sonication on ice in 500 mM triethylammonium
bicarbonate with 0.1% SDS. Protein concentrations were determined
using Bradford assay reagent (Sigma-Aldrich, Gillingham, UK). Label-
ing with iTRAQ reagents was then carried out according to the AB
SCIEX (Framingham, MA) protocol for an 8plex procedure as de-
scribed previously (24), but with the following modifications. Briefly,
100 g of protein from each sample was reduced with tris(2-carboxy-
ethyl)phosphine hydrochloride and capped with methyl methanethio-
sulfate before overnight digestion with trypsin (Promega). Peptides
were then labeled with isobaric tags, pooled, diluted to 5 ml with 10
mM potassium dihydrogen phosphate and 25% acetonitrile (ACN),
and acidified to pH 3 with phosphoric acid.
Sample Prefractionation and Desalting—Samples were fraction-
ated on a PolySULFOETHYL A strong cation-exchange column
(200  4.6 mm, 5 m, 300 Å; Poly LC, Columbia, MD) at 1 ml/min
using a gradient from 10 mM potassium dihydrogen phosphate and
25% (w/v) ACN to 0.5 M potassium chloride, 10 mM potassium
dihydrogen phosphate, and 25% (w/w/v) ACN over 75 min. Fractions
of 2 ml were collected and dried by centrifugation under vacuum
(SpeedVac, Eppendorf UK, Stevenage, UK). Fractions were reconsti-
tuted in 1 ml of 0.1% trifluoroacetic acid and desalted using an mRP
high-recovery protein column (4.6 50 mm; Agilent, Berkshire UK) on
a VISION workstation (Applied Biosystems/Life Technologies, Pais-
ley, UK) prior to MS analysis.
MS Analysis of iTRAQ Samples—Desalted fractions were reconsti-
tuted in 40 microliters of 0.1% formic acid, and 5 microliter aliquots
were delivered into a TripleTOF 5600 system (AB SCIEX) via an
Eksigent NanoUltra cHiPLC system (AB SCIEX) mounted with a mi-
crofluidic trap and an analytical column (15 cm  75 micrometer)
packed with ChromXP C18-CL (3 m). A NanoSpray III source was
fitted with a 10 m inner diameter PicoTip emitter (New Objective,
UM-CLL Associated with Lymphadenopathy
934 Molecular & Cellular Proteomics 14.4
Woburn, MA). The trap column was washed with 2% ACN and 0.1%
formic acid for 10 min at 2 microliter/min before switching in-line with
the analytical column. A gradient of 2–50% ACN and 0.1% (v/v)
formic acid over 90 min was applied to the column at a flow rate of
300 nl/min. Spectra were acquired automatically in positive ion mode
using information-dependent acquisition powered by Analyst TF 1.5.1
software (AB SCIEX). Up to 25 MS/MS spectra were acquired per
cycle (10 Hz) using a threshold of 100 counts/s and with dynamic
exclusion for 12 s. The rolling collision energy was increased auto-
matically by selecting the iTRAQ check box in Analyst and manually
by increasing the collision energy intercepts by 5.
iTRAQ Data Analysis—Data were searched using ProteinPilot 4.2
and the Paragon Algorithm (AB SCIEX) against the Swiss-Prot
database (2013-2, 40,646 human entries), with methyl methaneth-
iosulfate as a fixed modification of cysteine residues and biological
modifications allowed. Mass tolerance for precursor and fragment
ions was 10 ppm. The data were also searched against a reversed
decoy database, and only proteins lying within a 1% global false
discovery rate were taken forward for analysis (25, 26). Each 8plex
iTRAQ-MS experiment consisted of three M-CLL samples, three
UM-CLL samples, a replicate sample, and a common reference
sample consisting of a pool of all 18 samples. Quantitation of
proteins was relative to the common pooled sample present in each
iTRAQ-MS experiment. iTRAQ data for proteins identified by two or
more peptides with at least 90% confidence of correct sequence
assignment or by a single peptide with at least 99% confidence
were log2-transformed, batch-corrected using the Batch Remover
tool in the Partek Genomics Suite (version 6.3, Partek, St. Louis,
MO), and included in subsequent analyses. The MS proteomic data
have been deposited in the ProteomeXchange Consortium (27) via
the PRIDE partner repository with the data set identifiers
PXD001512, PXD001515, and PXD001516.
Principal Component Analysis (PCA)—PCA was performed using
the Partek Genomics Suite (version 6.3) to assess variance across the
sample set. A correlation method, which adjusts the data to be
standardized to a mean of zero and an S.D. of 1, was used for
dispersion matrix. Eigenvector scaling was performed orthogonal to
the original variables and scaled to unity.
Statistical Analysis—Statistical significance of the difference in
the levels of expression of proteins between UM-CLL and M-CLL
samples was determined using Student’s t test (two-tailed and
unpaired), and proteins whose levels of expression were signifi-
cantly different (p  0.05) were included in subsequent analyses.
Statistical analysis was conducted using the R computational en-
vironment (28).
Heat Maps—To detect outliers, hierarchical agglomerative cluster-
ing with complete linkage and Euclidean distance measure was em-
ployed on the selected data, and heat maps were drawn using the
heatmap.2 package in R (28).
Computational Functional Analysis—Proteins found to have signif-
icantly higher or lower levels of expression in UM-CLL samples by
iTRAQ-MS (p  0.05) were subjected to computational functional
analysis. Proteins were functionally classified using the Protein Anal-
ysis Through Evolutionary Relationships (PANTHER) classification
system. Pathway analysis was conducted using the GeneGo pathway
maps in the MetaCore database (version 6.14, build 61508; Thomson
Reuters, New York, NY). The Pathway Maps tool was used to enrich
for pathways, and p values were calculated based on a hypergeo-
metric distribution, with the default database used as the back-
ground. Significant pathway enrichment was defined as a false dis-
covery rate-corrected p  0.05.
Western Blotting—Proteins were separated on an SDS-polyacryl-
amide gel and transferred to Immobilon-P polyvinylidene difluoride
membranes (Millipore, Bedford, MA), which were probed with rat
monoclonal MNDA (myeloid cell nuclear differentiation antigen), rab-
bit monoclonal LEF-1 (lymphoid enhancer-binding factor 1), and rab-
bit polyclonal TCL-1 (T cell leukemia/lymphoma 1) antibodies (all from
Cell Signaling Technologies, New England Biolabs, Herts, UK), and
mouse monoclonal -actin antibody (Sigma-Aldrich). Immunoreactiv-
ity was detected by incubation with horseradish peroxidase-conju-
gated goat anti-rat IgG, anti-rabbit IgG, or anti-mouse IgG antibodies
(Santa Cruz Biotechnology, Insight Biotechnology, Middlesex, UK)
and an enhanced chemiluminescence kit (Millipore, Watford, UK),
with subsequent digitization using an Image Reader LAS-1000 (Fuji-
film, Tokyo, Japan). For quantification of the data, the images were
further analyzed on the same instrument using 2D Densitometry Aida
Image Analyzer software (Fujifilm). Mann-Whitney tests were used to
determine statistical significance of differences in the median values
of optical density of the signals corresponding to proteins of interest
in CLL samples between UM-CLL and M-CLL cases.
Transmigration Assay and CCR7 Expression—Transmigration as-
says were carried out as described previously (29), but with the
following modifications. Briefly, 5  105 CLL cells were added to
the inserts of Transwell plates (5 m pore size;Corning B.V., Am-
sterdam, The Netherlands). The CCL21 (CC chemokine ligand 21; 1
g/ml; R&D Systems Europe, Oxford, UK) was then added to the
bottom wells. The cells were incubated for 4 h at 37 °C with 5%
CO2. After incubation, the transmigrated cells from three technical
replicates were counted, and the migration index was calculated
(migration index  number of cells migrating in the presence of
TABLE I
Clinical features of the 18 CLL samples subjected to iTRAQ-MS
Clinical feature M-CLL (n  9) UM-CLL (n  9) p
Age at diagnosis (median), years 67 70 0.694
Gender (males/females) 3/6 6/3 0.347
Prior therapy (treated/untreated)a 3/6 2/7 0.620
Leukocyte count at time of sampling (median), 109/liter 78.4 135.8 0.423
High-risk chromosomal abnormalities (17p and/or 11q; yes/no)b 2/7 2/7 1.000
IGHV (median), %c 7.48 0.34 0.00004
The statistical significance of the difference (p values) between the two groups was determined using a two-tailed Mann-Whitney U test for
parametric data and Fisher’s exact test for nonparametric data, respectively.
a Prior therapy consisted of various combinations of glucocorticoid, chlorambucil, fludarabine, or fludarabine plus cyclophosphamide.
b CLL samples were tested by interphase fluorescence in situ hybridization for del17p13 (17p), del11q23 (11q), trisomy 12 (12), and
del13q14 (13q). 17p and 11q are regarded as high-risk chromosomal abnormalities.
c IGHV refers to somatic mutation in the IGHV gene of CLL cells compared with the gene sequence of the nearest germ line, where 2%
was classed as UM-CLL and 2% was classed as M-CLL.
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chemokine divided by number of cells migrating in the absence of
chemokine). The expression of the CCL21 receptor (CCR7) in CLL
cells was measured by FACS (Becton Dickinson, Oxford, UK).
RESULTS
Quantitative Proteomic Analysis Separates CLL Samples
Based on IGHV Mutational Status—To generate quantitative
information on the whole proteome of CLL cells, mononuclear
cells from nine M-CLL and nine UM-CLL samples containing
90% CLL cells were subjected to iTRAQ-based MS (Table
1). The two groups were well balanced in other respects,
including age at diagnosis (median of 67 versus 70 years),
prior therapy (37% versus 22%), and adverse chromosomal
abnormalities (22% versus 22%), although fewer M-CLL than
UM-CLL patients were male (33% versus 67%).
FIG. 1. Bioinformatic analysis of proteins identified by iTRAQ-MS. A, Venn diagram showing the number of proteins reproducibly
identified between the three separate iTRAQ-MS experiments. In total, 3521 proteins were identified, 2024 of which were identified in all three
experiments, and 2715 proteins were identified in two or more experiments. B, PCA showing the separation of UM-CLL and M-CLL samples
based on relative protein levels. C, volcano plot of the entire protein data set obtained by iTRAQ-based MS showing differences in protein
expression between M-CLL and UM-CLL according to magnitude and p value (t test). Protein expression was remarkably similar in the two CLL
subsets, with 92% (n  3247) of identified proteins sharing similar levels of expression across the sample cohort (p  0.05). However, 270
proteins were differentially expressed between the two CLL subsets, giving a p value of 0.05, with 147 proteins being expressed at lower
levels and 127 proteins expressed at higher levels in UM-CLL compared with M-CLL. D, heat map showing levels of differentially expressed
proteins for which relative quantitative values were obtained for all 18 CLL cases (n  186). Hierarchical clustering of CLL cases based on the
relative expression of these proteins generated two clusters comprising the nine cases of UM-CLL and the nine cases of M-CLL, respectively.
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A total of 3521 proteins were identified within a 1% global
false discovery rate and with a high confidence of correct
peptide sequence assignment (Fig. 1A and the full list of pro-
teins provided in the supplemental data). Of these, 2024 pro-
teins were identified in all three separate iTRAQ-MS experi-
ments (Fig. 1A). To determine whether protein expression was
similar between UM-CLL and M-CLL samples, we subjected
the data to PCA. As shown in Fig. 1B, PCA showed a distinc-
tion between UM-CLL and M-CLL samples based on protein
expression.
A two-tailed t test was used to determine the statistical
significance of differences in protein expression between UM-
CLL and M-CLL samples. As shown in Fig. 1C, protein ex-
pression was largely comparable between the two CLL sub-
sets, with 92% of proteins sharing similar levels of expression
across the sample cohort. However, we found 274 proteins
that were differentially expressed in UM-CLL and M-CLL sam-
ples (p  0.05) (supplemental Table S2). Among them, 127
proteins were expressed at higher levels and 147 proteins at
lower levels in UM-CLL samples compared with M-CLL coun-
terparts (Fig. 1C). Relative quantification of 186 of 274 differ-
entially expressed proteins was obtained across all 18 sam-
ples. As shown in Fig. 1D, hierarchical clustering of CLL
samples based on the expression of these 186 differentially
TABLE II
Chemotaxis, cell adhesion, and cytoskeletal remodeling pathway maps enriched by proteins found to be differentially expressed in M-CLL
versus UM-CLL
Enriched pathways p FDR
No. of differentially
expressed proteins
in pathway
Total proteins
in pathway
1. Cytoskeleton remodeling_Regulation of actin cytoskeleton by Rho GTPases 0.001 0.000 7 23
2. Chemotaxis_Inhibitory action of lipoxins on IL-8- and leukotriene B4-induced neutrophil
migration
0.001 0.000 8 51
3. Inhibitory action of lipoxins on neutrophil migration 0.001 0.000 8 57
4. Cell adhesion_Chemokines and adhesion 0.001 0.000 10 100
5. Cell adhesion_IL-8-dependent cell migration and adhesion 0.001 0.000 6 33
6. Chemotaxis_Leukocyte chemotaxis 0.001 0.000 8 75
7. Immune response_Immunological synapse formation 0.001 0.001 7 59
8. Cell adhesion_Histamine H1 receptor signaling in interruption of cell barrier integrity 0.001 0.001 6 45
9. Cytoskeleton remodeling_Integrin outside-in signaling 0.001 0.002 6 49
10. Cytoskeleton remodeling_Cytoskeleton remodeling 0.001 0.002 8 102
11. CCR4-dependent immune cell chemotaxis in asthma and atopic dermatitis 0.001 0.002 5 34
12. Development_S1PR1 signaling via -arrestin 0.001 0.002 5 34
13. Chemotaxis_CCR4-induced chemotaxis of immune cells 0.001 0.002 5 34
14. Mechanism of action of CCR4 antagonists in asthma and atopic dermatitis (Variant 1) 0.001 0.002 5 34
15. Immune response_CXCR4 signaling via second messenger 0.001 0.002 5 34
16. Chemotaxis_C5a-induced chemotaxis 0.001 0.005 5 43
17. Immune response_MIF-induced cell adhesion, migration and angiogenesis 0.001 0.006 5 46
18. Chemotaxis_Lipoxin inhibitory action on fMLP-induced neutrophil chemotaxis 0.001 0.006 5 46
19. Development_S1PR2 and S1PR3 in cell proliferation and differentiation 0.001 0.006 4 26
20. Development_Thromboxane A2 pathway signaling 0.001 0.007 5 49
21. Cytoskeleton remodeling_TGF, Wnt, and cytoskeletal remodeling 0.001 0.010 7 111
22. Immune response_CCL2 signaling 0.001 0.010 5 54
23. Cell adhesion_Integrin inside-out signaling 0.001 0.011 5 56
24. Chemotaxis_CXCR4 signaling pathway 0.001 0.012 4 34
25. Development_c-Kit ligand signaling pathway during hemopoiesis 0.001 0.014 5 61
26. Cell adhesion_Role of tetraspanins in integrin-mediated cell adhesion 0.002 0.015 4 37
27. Cytoskeleton remodeling_1A-Adrenergic receptor-dependent inhibition of PI3K 0.002 0.019 3 19
28. Cytoskeleton remodeling_Role of PKA in cytoskeleton reorganization 0.002 0.019 4 40
29. Development_S1PR3 signaling pathway 0.003 0.023 4 43
30. Chemotaxis_CCL2-induced chemotaxis 0.007 0.042 4 56
31. Muscle contraction_S1PR2-mediated smooth muscle contraction 0.008 0.044 3 30
32. Cytoskeleton remodeling_RalA regulation pathway 0.008 0.044 3 30
33. Cytoskeleton remodeling_Reverse signaling by ephrin B 0.008 0.046 3 31
34. Cell adhesion_4 integrins in cell migration and adhesion 0.011 0.057 3 34
35. G-protein signaling_S1PR2 signaling 0.012 0.059 3 35
36. Cell adhesion_Tight junctions 0.013 0.062 3 36
37. Development_S1PR1 signaling pathway 0.022 0.088 3 44
38. Development_S1PR4 signaling pathway 0.036 0.122 2 22
39. Immune response_IL-33 signaling pathway 0.043 0.134 3 57
40. Immune response_IL-18 signaling 0.048 0.144 3 60
41. Immune response_IL-17 signaling pathways 0.048 0.144 3 60
42. Cell adhesion_Cadherin-mediated cell adhesion 0.049 0.144 2 26
43. Development_Cross-talk between VEGF and angiopoietin 1 signaling pathways 0.049 0.144 2 26
FDR, false discovery rate; MIF, migration inhibitory factor; fMLP, formylmethionylleucylphenylalanine.
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expressed proteins clearly separated cases into two distinct
groups corresponding to IGHV mutational status, with no
samples identified as outliers.
Verification of iTRAQ-MS Data by Western Blotting—To
validate the iTRAQ-MS data, we sought to verify the differen-
tial expression of a small number of proteins by Western
blotting. We selected three differentially expressed proteins
as follows: TCL-1 (30, 31), MNDA (32), and LEF-1 (33). The
expression of TCL-1, MNDA, and LEF-1 as measured by
Western blotting varied among the 18 samples (supplemental
Fig. S1A) and correlated with IGHV mutational status with a
pattern of differential expression entirely consistent with the
iTRAQ-MS data (supplemental Fig. S1B).
UM-CLL Cells Are Characterized by Defective Cell Migra-
tion Pathways—We next used GeneGo pathway maps from
MetaCore to identify pathways enriched by the 274 proteins
that were differentially expressed in the two subsets of CLL
samples (p  0.05). The enrichment analysis identified 169
signaling pathways (p  0.05) (supplemental Table S3). Re-
markably, 26 of the top 50 most significantly altered pathways
were associated with cell migration/adhesion. In total, 43 cell
migration/adhesion pathways (Table 2) were significantly en-
riched by 39 differentially expressed proteins (Table 3). As all
of these 39 proteins were involved in lymphocyte entry into,
transit within, or exit from the lymphoid tissues (Fig. 2) and 35
of them were expressed at significantly lower levels in UM-
TABLE III
39 individual proteins differentially expressed in M-CLL versus UM-CLL (p  0.05) that are involved in chemotaxis, cell adhesion, and
cytoskeletal remodeling pathways
Swiss-Prot
accession No.
Gene Protein name
Fold change
(UM/M)
p
P68032 Actin cytoskeletal Actin,  cardiac muscle 1a 1.5 0.011
P63261 Actin cytoskeletal Actin, cytoplasmic 2 2.7 0.014
O15143 Arp2/3 Actin-related protein 2/3 complex subunit 1B 1.4 0.038
O15144 Arp2/3 Actin-related protein 2/3 complex subunit 2 1.8 0.001
O15145 Arp2/3 Actin-related protein 2/3 complex subunit 3 1.6 0.014
P61158 Arp2/3 Actin-related protein 3 1.6 0.031
P62330 ARF6 ADP-ribosylation factor 6 1.8 0.013
P35611 Adducin 1 () -Adducin 1.6 0.004
P63010 Actin cytoskeletal AP-2 complex subunit  1.5 0.010
Q96CW1 AP complex 2 medium () chain AP-2 complex subunit  2.2 0.014
P16070 CD44 CD44 antigen 1.4 0.012
O43639 GRB4/NCK2 Cytoplasmic protein NCK2a 1.3 0.045
Q92608 DOCK2 Dedicator of cytokinesis protein 2 1.8 0.037
Q02750 MEK1/2 Dual specificity mitogen-activated protein kinase kinase 1 1.4 0.007
P50570 Dynamin-2 Dynamin-2 1.3 0.048
P02675 Fibrinogen Fibrinogen  chain 6.0 0.049
P02679 Fibrinogen  Fibrinogen  chain 9.3 0.044
P21333 Filamin Filamin-A 3.0 0.006
P04899 G protein i family Guanine nucleotide-binding protein Gi subunit -2 1.6 0.006
P20036 MHC class II HLA class II histocompatibility antigen, DP 1 chain 2.0 0.020
O14920 IKK- Inhibitor of nuclear factor B kinase subunit  1.3 0.017
P20701 L integrin Integrin L 2.1 0.023
P11215 M integrin Integrin M 2.6 0.010
P05107 ITGB2/L integrin Integrin 2 2.3 0.046
Q9UJU2 Tcf/LEF-1 Lymphoid enhancer-binding factor 1 1.2 0.019
P49137 MAPKAP MAPK-activated protein kinase 2a 1.4 0.043
P60660 MELC/myosin Myosin light polypeptide 6 1.8 0.023
P24844 MRLC/myosin Myosin regulatory light polypeptide 9 5.5 0.029
P35579 Myosin Myosin-9 2.9 0.002
Q00653 NF-B Nuclear factor NF-B p100 subunit 1.3 0.035
Q14289 FAK2/Pyk2 Protein-tyrosine kinase 2 1.4 0.038
Q7LDG7 CalDAG-GEFI RAS guanyl-releasing protein 2 2.2 0.006
P08575 CD45 Receptor-type tyrosine-protein phosphatase C 1.7 0.009
Q92888 ARHGEF1 Rho guanine nucleotide exchange factor 1 1.5 0.049
P51812 p90RSK Ribosomal protein S6 kinase 3 1.5 0.006
P42229 STAT5 Signal transducer and activator of transcription 5A 1.9 0.028
Q9Y490 Talin Talin-1 3.5 0.015
P07996 Thrombospondin-1 Thrombospondin-1 5.2 0.017
P50552 VASP Vasodilator-stimulated phosphoprotein 1.8 0.050
All proteins were identified by two or more peptides at 90% confidence and were present in two or more iTRAQ experiments unless
indicated otherwise.
a Proteins were identified by a single peptide at 99% confidence and were present in two or more iTRAQ experiments.
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CLL samples, these results suggest that UM-CLL cells have
reduced migratory properties compared with their M-CLL
counterparts.
The lymphocyte chemotaxis pathway, which is essential for
migration into and transit within lymphoid tissues (34), was
significantly altered (p  0.001) in UM-CLL cells. Of particular
note, eight of the nine differentially expressed proteins in this
pathway were expressed at significantly lower levels in UM-
CLL samples (Fig. 3). These underexpressed proteins in-
cluded the Rap (Ras-related protein) activator CalDAG-GEFI
(RAS guanyl-releasing protein 2; Q7LDG7), which is involved
in integrin activation (35, 36); both chains of the L2 integrin
(P20701 and P05107), which is required for the migration of
lymphocytes into lymph nodes; and talin (Q9Y490), which is
important in maintaining the high-affinity binding state of
L2 (37). Collectively, these observations strongly suggest
that UM-CLL is associated with impaired Rap1-dependent
L2-mediated migration.
We also found that CD44 (P16070), which facilitates the ad-
hesion of CLL cells within the lymph node microenvironment
(38), was expressed at significantly higher levels in UM-CLL
cells, whereas two proteins that regulate S1PR1 (sphingosine
1-phosphate receptor 1) signaling, dynamin-2 (P50570) and
G-protein i (P04899) (39, 40), were expressed at significantly
lower levels. Because egress of lymphocytes from lymph nodes
is absolutely dependent on S1PR1 (41), these findings suggest
that the latter process is also dysfunctional in UM-CLL. In
keeping with the GeneGo MetaCore pathway analysis, PAN-
THER analysis indicated that many of the proteins that were
expressed at reduced levels in UM-CLL cells are involved in
cytoskeletal remodeling (supplemental Fig. S2, A and B).
UM-CLL Cells Retain Their Ability to Migrate toward CCL21—
The proteomic data suggest that UM-CLL cells have migra-
tion defects that affect both lymph node entry and exit. To
formulate a hypothesis that could be validated at the clinical
level, we examined one of the key steps involved in the entry
FIG. 2. Schematic diagram illus-
trating factors involved in lympho-
cyte migration into, retention
within, and egress from lymph
nodes. Migration into, within, and
through lymphoid tissues is a com-
plex multistep process. The major
steps are illustrated here, along with
the pathways/proteins that are altered
in UM-CLL versus M-CLL. On initial
contact with the endothelium, the
lymphocytes become loosely tethered
(A). If the cell encounters chemokine
presented on the endothelial cell sur-
face, it then becomes firmly adherent
in a process involving integrin activa-
tion and chemokine signaling (B). The
cell then crawls along the endothelium
until it reaches an intercellular junc-
tion, where it undergoes diapedesis in
response to chemokine (C); this proc-
ess also requires integrin activation.
Once within the lymphoid tissue (D),
two different mechanisms mediate the
adherence of CLL cells within the tis-
sues; these involve 41 and CD44
binding to their respective ligands, fi-
bronectin and hyaluronan. Adhesion
mediated by both substrata is influ-
enced by chemokine signaling. The
final step of transit though the lymph
node is egress (E), a process that is
entirely dependent on S1PR1 and is
independent of integrins.
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FIG. 3. Enrichment of leukocyte chemotaxis pathway by proteins found to be differentially expressed in M-CLL versus UM-CLL. One
of the migration pathways most enriched by the GeneGo MetaCore pathway maps using proteins differentially expressed between UM-CLL
and M-CLL was the leukocyte chemotaxis pathway (p 0.001). This pathway directs leukocyte movement to lymphatic organs and also allows
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of CLL cells into lymph nodes, namely, migration toward
CCL21. To ascertain the functional integrity of this aspect of
lymph node entry in light of our published observations that
integrin activation on CLL cells is defective (29, 42, 43), CLL
cells were examined for their ability to migrate in the absence
of adhesion using Transwell assays. Although the UM-CLL
cells tended to migrate less than the M-CLL cells, no signifi-
cant differences were observed (p  0.713) (supplemental
Fig. S3). These data therefore support the notion that UM-CLL
cells at least partly retain their ability to migrate toward CCL21
and are therefore able to enter the lymph node environment.
Patients with UM-CLL Have More Lymphadenopathy than
Those with M-CLL—On the basis of our proteomic and func-
tional data, we hypothesized that UM-CLL cells are retained in
lymph nodes due to a global defect in migration coupled with
impaired S1PR1-mediated egress and increased adhesion to
hyaluronan within the tissue via CD44. To test this hypothesis,
we examined the clinical records of patients with M-CLL (n 
78) and UM-CLL (n  42) for documentation of lymph node
enlargement. To be able to analyze lymphadenopathy inde-
pendently of overall tumor burden, cases of CLL used for this
comparison were selected to have similar levels of blood
involvement; this was achieved by setting an upper limit for
the blood leukocyte count of 130  109/liter. In keeping with
our hypothesis, twice as many patients with UM-CLL com-
pared with M-CLL had documented lymphadenopathy (50%
versus 24%; p  0.01) (Table 4). As expected, there was no
significant difference in the leukocyte count between the two
groups selected for this comparison (medians of 37 109/liter
and 28  109/liter, respectively; p  0.05). This indicates that
the increased lymphadenopathy observed in UM-CLL is not
simply a nonspecific manifestation of increased tumor burden
but instead reflects the selective retention of UM-CLL cells in
lymph nodes.
Other Pathways Enriched by Differentially Expressed Pro-
teins—Although the most striking difference between M-CLL
and UM-CLL cells identified by proteomic analysis was the
defect in cell migration pathways in the IGHV-unmutated
group, other differences were also observed. For example,
PANTHER analysis showed that the majority of proteins that
were overexpressed in UM-CLL cells are involved in nucleic
acid binding and RNA splicing factor activity (supplemental
Fig. S2, C and D), suggesting higher levels of transcriptional
and translational activities in these cells. Furthermore,
GeneGo MetaCore analysis showed that pathways that pro-
mote cell survival and proliferation in UM-CLL cells were
significantly enriched (supplemental Table S3). These path-
ways included the immune response pathway involving B cell
receptor signaling (p  0.006) (supplemental Fig. S4), the
endoplasmic reticulum stress response pathway (p  0.035)
(supplemental Fig. S5), and the Wnt signaling pathway (p 
0.006), where LEF-1, a critical transcription factor in this path-
way (44), was significantly overexpressed in UM-CLL cells
(p  0.019 and 0.004 for iTRAQ-based MS and Western blot
confirmation, respectively).
DISCUSSION
The aim of this study was to elucidate pathogenetic mech-
anisms responsible for the adverse clinical course of UM-CLL
by comparing the proteome of M-CLL and UM-CLL cells.
Using iTRAQ-MS, we analyzed the total proteome of 18 pri-
mary CLL samples and identified 3521 proteins, making this
the largest proteomic study hitherto conducted in CLL. In
agreement with previous mRNA profiling studies (8, 9), overall
protein expression in the nine UM-CLL and nine M-CLL sam-
ples was largely comparable, with 92% of identified proteins
sharing similar levels of expression. However, almost 8% of
proteins were differentially expressed. This contrasts with the
much lower proportion of genes (1%) that were found to be
differentially expressed in mRNA profiling studies (8, 9, 45). It
can therefore be deduced that post-transcriptional regulation
is an important determinant of gene expression in CLL and
that differences in gene expression between M-CLL and UM-
CLL are substantially greater at the protein than mRNA level.
them to migrate to sites of infection and/or inflammation via either L2 or 41 integrins (highlighted). Within this pathway, nine proteins were
found to be differentially expressed: MHC class II (P20036, p  0.02), G-protein i family (P04899, p  0.006), CalDAG-GEFI (Q7LDG7, p 
0.006), ARF6 (P62330, p 0.013), actin (P68032, p 0.011), actin cytoskeletal (P63261, p 0.014), talin (Q9Y490, p 0.015), ITGB2 (P05107,
p  0.046), and L2 (P20701, p  0.023; P05107, p  0.046). MHC class II had a higher expression in UM-CLL (fold changes represented
by a red thermometer). However, the other eight differentially expressed proteins had a lower expression in UM-CLL (fold changes represented
by blue thermometers) compared with M-CLL. This suggests that migration into the tissue microenvironments via the L2 integrin pathway
may be dysfunctional in UM-CLL.
TABLE IV
Relationship between IGHV mutational status and lymphadenopathy
in 120 CLL patients
Clinical feature
M-CLL
(n  78)
UM-CLL
(n  42)
p
Age (median), years 67 69 0.589
Gender (males/females) 44/34 20/22 0.443
Prior therapy (treated/untreated) 3/61 1/32 1.000
Leukocyte count (median), 109/liter 28.25 37.35 0.072
Lymphadenopathy 1.5 cm (yes/no) 19/59 21/21 0.0078
The extended cohort comprised all locally stored CLL cases for
which IGHV mutational status was known, information on lymphad-
enopathy available, and leukocyte count 130  109/liter. The sta-
tistical significance of the difference (p values) between the two
groups was determined using a two-tailed Mann-Whitney U test for
parametric data and Fisher’s exact test for nonparametric data, re-
spectively. All information presented relates to the time of sample
collection.
UM-CLL Associated with Lymphadenopathy
Molecular & Cellular Proteomics 14.4 941
In keeping with this observation, it is noteworthy that PCA
clearly separated CLL samples into two groups correspond-
ing to IGHV mutational status.
After verifying the differential expression of three proteins
(i.e., TCL-1, MNDA, and LEF-1), the iTRAQ-MS data were
subjected to two different forms of computational analyses to
explore the functional implications of the 274 differentially
expressed proteins. Strikingly, both GeneGo MetaCore path-
way analysis and PANTHER analysis of individual proteins
revealed that a high proportion of differentially expressed
proteins were involved in cell migration processes and that
almost all of these were underexpressed in UM-CLL. It can
therefore be concluded that UM-CLL cells have a global de-
fect in migration.
With regard to specific migration pathways that are defec-
tive in UM-CLL, the results of the computational analysis may
at first appear contradictory. Thus, although UM-CLL cells
underexpressed proteins involved in egress from lymph
nodes (dynamin-2 and G-protein i, which activate S1PR1),
they also underexpressed proteins involved in lymph node
entry (L2 integrin and CalDAG-GEFI, which activate L2
via Rap1, and talin, which stabilizes the integrin in its active
conformation). UM-CLL cells also overexpressed CD44,
which contributes to the retention of CLL cells in lymph nodes
by mediating adhesion to hyaluronan following engagement
of CD40 by CD154-expressing T cells in the lymph node
microenvironment (38). The overall impact of these different
pathway defects clearly depends on which are functionally
most important. Pertinent to this consideration is our previous
demonstration that Rap1-dependent L2 activation is de-
fective in CLL but that this defect can be overcome if 41 is
coexpressed (43). Other groups have shown that surface
41 expression is higher in UM-CLL (46). We therefore spec-
ulated that the L2 defect in UM-CLL cells is counteracted
by their increased surface expression of 41. In keeping with
this idea, we found that UM-CLL cells at least partially retain
their ability to migrate toward CCL21, which is required for
lymph node entry (42, 47). This led us to formulate the
hypothesis that in UM-CLL, defective lymph node entry is
more than compensated for by enhanced retention and
impaired egress, resulting in the selective accumulation of
the malignant cells in lymph nodes. To test this hypothesis,
we related lymph node enlargement to IGHV status in a
cohort of 120 patients and observed that lymphadenopathy
was twice as common in patients with UM-CLL compared
with those with M-CLL. The association between UM-CLL
and lymph node enlargement was not simply a reflection of
increased tumor burden, as the M-CLL and UM-CLL pa-
tients used for this comparison had similar levels of blood
involvement.
Retention of CLL cells in lymph nodes is likely to have
profound implications for disease pathogenesis, given that
the lymph node microenvironment provides crucial prolifera-
tive stimuli (48–50) and that lymph node enlargement is as-
sociated with adverse clinical outcome (51–53). In keeping
with this concept, PANTHER analysis revealed that the ma-
jority of proteins that were overexpressed in UM-CLL cells
had nucleic acid binding and RNA splicing factor activity. It is
also of interest that UM-CLL cells displayed a pattern of
protein expression indicating increased activity in B cell re-
ceptor signaling, endoplasmic reticulum stress response, and
Wnt signaling pathways. These properties of UM-CLL cells
could be intrinsic to their differentiation/maturation status.
Alternatively, they could represent changes induced by extrin-
sic stimuli during their delayed passage through the lymph
node microenvironment that are retained after the cells have
re-entered the blood stream.
The concept that UM-CLL cells are preferentially retained in
lymph nodes, where they are exposed to proliferative stimuli,
suggests that therapeutic strategies that displace CLL cells
from lymph nodes may be particularly effective in UM-CLL. In
agreement with this prediction, clinical studies have shown
that the overall response to ibrutinib, an inhibitor of Bruton
tyrosine kinase that redistributes CLL cells from tissues into
the blood by preventing tissue adhesion and homing (54–56),
is significantly higher in patients with UM-CLL (77%) com-
pared with those with M-CLL (33%) (p  0.005) (57). Very
similar findings have been observed with idelalisib (58), a
selective inhibitor of the phosphoinositide 3-kinase p110
delta isoform that mobilizes CLL cells into the blood by inter-
fering with microenvironmental interactions (59, 60).
In conclusion, we have shown that quantitative analysis of
the total proteome by iTRAQ-MS was able to separate indi-
vidual CLL cases according to IGHV status and explain the
more aggressive clinical behavior of UM-CLL and its particu-
lar sensitivity to treatments that induce anatomical displace-
ment from the lymph node microenvironment. More generally,
and in accordance with the ability of proteomic analysis to
detect alterations in gene expression resulting from both tran-
scriptional and post-transcriptional mechanisms (61, 62), the
study illustrates the considerable potential of iTRAQ-MS cou-
pled with a systems biology approach to elucidate pathogenetic
mechanisms and indicate therapeutic strategies in cancer.
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